| scholarly article | Q13442814 |
| P50 | author | Alzheimer's Disease Neuroimaging Initiative | Q4738819 |
| Paul S. Aisen | Q30299891 | ||
| Michael W. Weiner | Q56850515 | ||
| Reisa Sperling | Q56862977 | ||
| William J. Jagust | Q56863004 | ||
| Niklas Mattsson | Q57012884 | ||
| Philip S Insel | Q89149506 | ||
| P2093 | author name string | Michael Donohue | |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cerebrospinal fluid | Q54196 |
| P304 | page(s) | 554-560 | |
| P577 | publication date | 2015-05-01 | |
| P1433 | published in | JAMA Neurology | Q276813 |
| P1476 | title | Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls | |
| P478 | volume | 72 |
| Q36918859 | Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology |
| Q89751795 | Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity |
| Q53397201 | Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis. |
| Q92352606 | CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease |
| Q64064005 | Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers |
| Q48547464 | Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents. |
| Q28273817 | Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography |
| Q47587631 | Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry |
| Q37307467 | Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease |
| Q36383749 | Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease |
| Q46045880 | Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity |
| Q92342875 | Genome-wide association study identifies CBFA2T3 affecting the rate of CSF Aβ42 decline in non-demented elders |
| Q40285515 | Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects |
| Q30981669 | Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2 |
| Q51305325 | Mild Cognitive Impairment. |
| Q59843511 | Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals |
| Q42643417 | Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations |
| Q90644085 | Prediction of rapid amyloid and phospotylated-Tau accumulation in cognitively healthy individuals |
| Q47324557 | Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease. |
| Q38704916 | Rethinking on the concept of biomarkers in preclinical Alzheimer's disease |
| Q37451440 | The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans |
| Q36733387 | The Structural and Functional Connectome and Prediction of Risk for Cognitive Impairment in Older Adults |
| Q47134402 | The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design |
| Q50133231 | The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer's disease |
| Q37640765 | Unbiased estimates of cerebrospinal fluid β-amyloid 1-42 cutoffs in a large memory clinic population |
Search more.